All Stories

GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival fell short of expectations.

May 13, 2025 - 14:48
 0
GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs
GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival fell short of expectations.
Read More

Tags:

Previous Article

All the Beauty Retail Expansions of 2025

Next Article

Leap halves head count, narrows lead cancer drug's focus amid 'difficult market ...

Related Posts

Arcturus stops work on early-stage vaccine programs in effort to ‘streamline resources’

Arcturus stops work on early-stage vaccine programs in ...

May 13, 2025  0

FDA approves Teal Health’s HPV screening test as an at-home alternative to the Pap smear

FDA approves Teal Health’s HPV screening test as an at-...

May 9, 2025  0

GSK posts phase 3 itch data as it closes in on FDA approval

GSK posts phase 3 itch data as it closes in on FDA appr...

May 8, 2025  0